DA32 Life Science Tech Acquisition Stock Forecast, Price & News

DA32 Life Science Tech Acquisition (NASDAQ:DALS) Frequently Asked Questions

Are investors shorting DA32 Life Science Tech Acquisition?

DA32 Life Science Tech Acquisition saw a decrease in short interest in October. As of October 29th, there was short interest totaling 14,200 shares, a decrease of 23.7% from the October 14th total of 18,600 shares. Based on an average daily trading volume, of 14,500 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.1% of the shares of the company are sold short.
View DA32 Life Science Tech Acquisition's Short Interest.

Who are some of DA32 Life Science Tech Acquisition's key competitors?

Some companies that are related to DA32 Life Science Tech Acquisition include Apollo Strategic Growth Capital (APSG), Bain Capital Specialty Finance (BCSF), Brooge Energy (BROG), CONX (CONX), Apollo Strategic Growth Capital II (APGB), Pontem (PNTM), CC Neuberger Principal Holdings II (PRPB), Paya (PAYA), Elliott Opportunity II (EOCW), NextNav (NN), Avanti Acquisition (AVAN), Vivid Seats (SEAT), Liberty Media Acquisition (LMACA), RedBall Acquisition (RBAC) and MSD Acquisition (MSDA).
View all of DALS's competitors.

When did DA32 Life Science Tech Acquisition IPO?

(DALS) raised $200 million in an initial public offering on Wednesday, July 28th 2021. The company issued 20,000,000 shares at $10.00 per share.

What is DA32 Life Science Tech Acquisition's stock symbol?

DA32 Life Science Tech Acquisition trades on the NASDAQ under the ticker symbol "DALS."

When does the company's lock-up period expire?

DA32 Life Science Tech Acquisition's lock-up period expires on Monday, January 24th. DA32 Life Science Tech Acquisition had issued 20,000,000 shares in its public offering on July 28th. The total size of the offering was $200,000,000 based on an initial share price of $10.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are DA32 Life Science Tech Acquisition's major shareholders?

DA32 Life Science Tech Acquisition's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (12.07%), Deerfield Management Company L.P. Series C (6.24%), BlackRock Inc. (5.85%), RA Capital Management L.P. (5.85%), Magnetar Financial LLC (3.63%) and Millennium Management LLC (3.52%).

Which institutional investors are buying DA32 Life Science Tech Acquisition stock?

DALS stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Deerfield Management Company L.P. Series C, RA Capital Management L.P., BlackRock Inc., Magnetar Financial LLC, Millennium Management LLC, Moore Capital Management LP, and Citadel Advisors LLC.

How do I buy shares of DA32 Life Science Tech Acquisition?

Shares of DALS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DA32 Life Science Tech Acquisition's stock price today?

One share of DALS stock can currently be purchased for approximately $9.84.

How much money does DA32 Life Science Tech Acquisition make?

DA32 Life Science Tech Acquisition has a market capitalization of $252.40 million.

How many employees does DA32 Life Science Tech Acquisition have?

DA32 Life Science Tech Acquisition employs 2,021 workers across the globe.

How can I contact DA32 Life Science Tech Acquisition?

The company can be reached via phone at 212551600.